Cargando…

Pattern of Recurrence and Patient Survival after Perioperative Chemotherapy with 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) for Locally Advanced Esophagogastric Adenocarcinoma in Patients Treated Outside Clinical Trials

Background: The 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) protocol provides superior oncologic results compared to other perioperative chemotherapeutic protocols for the treatment of non-metastatic esophagogastric cancer (EGAC). Survival and the pattern of recurrence of EGAC after FLOT and...

Descripción completa

Detalles Bibliográficos
Autores principales: Glatz, Torben, Verst, Rasmus, Kuvendjiska, Jasmina, Bronsert, Peter, Becker, Heiko, Hoeppner, Jens, Kulemann, Birte
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7464040/
https://www.ncbi.nlm.nih.gov/pubmed/32824326
http://dx.doi.org/10.3390/jcm9082654
_version_ 1783577272792383488
author Glatz, Torben
Verst, Rasmus
Kuvendjiska, Jasmina
Bronsert, Peter
Becker, Heiko
Hoeppner, Jens
Kulemann, Birte
author_facet Glatz, Torben
Verst, Rasmus
Kuvendjiska, Jasmina
Bronsert, Peter
Becker, Heiko
Hoeppner, Jens
Kulemann, Birte
author_sort Glatz, Torben
collection PubMed
description Background: The 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) protocol provides superior oncologic results compared to other perioperative chemotherapeutic protocols for the treatment of non-metastatic esophagogastric cancer (EGAC). Survival and the pattern of recurrence of EGAC after FLOT and curative tumor resection are analyzed in a collective of patients treated outside clinical trials. Methods: Two-hundred-seventy-seven patients with EGAC (cT3-4 and/or cN+) were treated with perioperative FLOT-chemotherapy plus curative surgery between 2009 and 2018. Data were analyzed retrospectively from a prospective database. Results: Two-hundred-twenty-eight patients were included in the analysis. Postoperative in-hospital mortality was 2%. The median survival was 61–months, and median recurrence-free survival was 42 months. Multivariate analysis identified postoperative nodal status and T-stage as independent predictors of improved overall and recurrence-free survival. Administration of adjuvant chemotherapy failed to be significant for overall survival but was an independent predictor of recurrence-free survival. Recurrence occurred after a median of 9 months (range 1–46 months). Eighty-nine percent of recurrence occurred during the first 24 months. The rate of local recurrence was low. After surgery for gastric cancer, the major recurrence site was peritoneal carcinomatosis (56%), while esophageal cancer recurred mostly as metastasis to distant organs (78%). The specific site of recurrence had no impact on overall survival time. Conclusion: Real-life application of FLOT shows oncologic results comparable to clinical trials. Recurrence after FLOT and surgery for EGAC occurs predominantly early within the first two years after surgery and in the form of distant organ metastasis for esophageal tumors or peritoneal carcinomatosis for gastric tumors.
format Online
Article
Text
id pubmed-7464040
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-74640402020-09-04 Pattern of Recurrence and Patient Survival after Perioperative Chemotherapy with 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) for Locally Advanced Esophagogastric Adenocarcinoma in Patients Treated Outside Clinical Trials Glatz, Torben Verst, Rasmus Kuvendjiska, Jasmina Bronsert, Peter Becker, Heiko Hoeppner, Jens Kulemann, Birte J Clin Med Article Background: The 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) protocol provides superior oncologic results compared to other perioperative chemotherapeutic protocols for the treatment of non-metastatic esophagogastric cancer (EGAC). Survival and the pattern of recurrence of EGAC after FLOT and curative tumor resection are analyzed in a collective of patients treated outside clinical trials. Methods: Two-hundred-seventy-seven patients with EGAC (cT3-4 and/or cN+) were treated with perioperative FLOT-chemotherapy plus curative surgery between 2009 and 2018. Data were analyzed retrospectively from a prospective database. Results: Two-hundred-twenty-eight patients were included in the analysis. Postoperative in-hospital mortality was 2%. The median survival was 61–months, and median recurrence-free survival was 42 months. Multivariate analysis identified postoperative nodal status and T-stage as independent predictors of improved overall and recurrence-free survival. Administration of adjuvant chemotherapy failed to be significant for overall survival but was an independent predictor of recurrence-free survival. Recurrence occurred after a median of 9 months (range 1–46 months). Eighty-nine percent of recurrence occurred during the first 24 months. The rate of local recurrence was low. After surgery for gastric cancer, the major recurrence site was peritoneal carcinomatosis (56%), while esophageal cancer recurred mostly as metastasis to distant organs (78%). The specific site of recurrence had no impact on overall survival time. Conclusion: Real-life application of FLOT shows oncologic results comparable to clinical trials. Recurrence after FLOT and surgery for EGAC occurs predominantly early within the first two years after surgery and in the form of distant organ metastasis for esophageal tumors or peritoneal carcinomatosis for gastric tumors. MDPI 2020-08-16 /pmc/articles/PMC7464040/ /pubmed/32824326 http://dx.doi.org/10.3390/jcm9082654 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Glatz, Torben
Verst, Rasmus
Kuvendjiska, Jasmina
Bronsert, Peter
Becker, Heiko
Hoeppner, Jens
Kulemann, Birte
Pattern of Recurrence and Patient Survival after Perioperative Chemotherapy with 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) for Locally Advanced Esophagogastric Adenocarcinoma in Patients Treated Outside Clinical Trials
title Pattern of Recurrence and Patient Survival after Perioperative Chemotherapy with 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) for Locally Advanced Esophagogastric Adenocarcinoma in Patients Treated Outside Clinical Trials
title_full Pattern of Recurrence and Patient Survival after Perioperative Chemotherapy with 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) for Locally Advanced Esophagogastric Adenocarcinoma in Patients Treated Outside Clinical Trials
title_fullStr Pattern of Recurrence and Patient Survival after Perioperative Chemotherapy with 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) for Locally Advanced Esophagogastric Adenocarcinoma in Patients Treated Outside Clinical Trials
title_full_unstemmed Pattern of Recurrence and Patient Survival after Perioperative Chemotherapy with 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) for Locally Advanced Esophagogastric Adenocarcinoma in Patients Treated Outside Clinical Trials
title_short Pattern of Recurrence and Patient Survival after Perioperative Chemotherapy with 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) for Locally Advanced Esophagogastric Adenocarcinoma in Patients Treated Outside Clinical Trials
title_sort pattern of recurrence and patient survival after perioperative chemotherapy with 5-fu, leucovorin, oxaliplatin and docetaxel (flot) for locally advanced esophagogastric adenocarcinoma in patients treated outside clinical trials
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7464040/
https://www.ncbi.nlm.nih.gov/pubmed/32824326
http://dx.doi.org/10.3390/jcm9082654
work_keys_str_mv AT glatztorben patternofrecurrenceandpatientsurvivalafterperioperativechemotherapywith5fuleucovorinoxaliplatinanddocetaxelflotforlocallyadvancedesophagogastricadenocarcinomainpatientstreatedoutsideclinicaltrials
AT verstrasmus patternofrecurrenceandpatientsurvivalafterperioperativechemotherapywith5fuleucovorinoxaliplatinanddocetaxelflotforlocallyadvancedesophagogastricadenocarcinomainpatientstreatedoutsideclinicaltrials
AT kuvendjiskajasmina patternofrecurrenceandpatientsurvivalafterperioperativechemotherapywith5fuleucovorinoxaliplatinanddocetaxelflotforlocallyadvancedesophagogastricadenocarcinomainpatientstreatedoutsideclinicaltrials
AT bronsertpeter patternofrecurrenceandpatientsurvivalafterperioperativechemotherapywith5fuleucovorinoxaliplatinanddocetaxelflotforlocallyadvancedesophagogastricadenocarcinomainpatientstreatedoutsideclinicaltrials
AT beckerheiko patternofrecurrenceandpatientsurvivalafterperioperativechemotherapywith5fuleucovorinoxaliplatinanddocetaxelflotforlocallyadvancedesophagogastricadenocarcinomainpatientstreatedoutsideclinicaltrials
AT hoeppnerjens patternofrecurrenceandpatientsurvivalafterperioperativechemotherapywith5fuleucovorinoxaliplatinanddocetaxelflotforlocallyadvancedesophagogastricadenocarcinomainpatientstreatedoutsideclinicaltrials
AT kulemannbirte patternofrecurrenceandpatientsurvivalafterperioperativechemotherapywith5fuleucovorinoxaliplatinanddocetaxelflotforlocallyadvancedesophagogastricadenocarcinomainpatientstreatedoutsideclinicaltrials